NCT00582075View on ClinicalTrials.gov

Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

October 31, 2008

Study Completion Date

June 30, 2015

Conditions
CancerBrain Metastases
Interventions
DRUG

temozolomide

TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5

Trial Locations (1)

35233

University of Alabama at Birmingham, Birmingham

Sponsors
All Listed Sponsors
collaborator

Integrated Therapeutics Group

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT00582075 - Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases | Biotech Hunter | Biotech Hunter